企业理念Corporate

DainipponSumitomoPharmaCo.,Ltd.DainipponSumitomoPharmaCo.,Ltd.1CorporateMissionTobroadlycontributetosocietythroughvaluecreationbasedoninnovativeresearchanddevelopmentactivitiesforthebettermentofhealthcareandfullerlivesofpeopleworldwide’ThisdocumentisnotadisclosuredocumentundertheSecuritiesandExchangeLaw.Accordingly,neitheraccuracynorcompletenessoftheinformationcontainedhereinisguaranteed.ForecastsandotherinformationprovidedinthisdocumentarebasedontheinformationavailableatthetimeofannouncementofthefinancialresultsfortheSecondQuarteroftheYearEndingMarch31,2010(asofOctober29,2009)andactualresultsmaydiffermateriallyfromtheforecastshereinduetovariousfactors.Therefore,youareadvisedtorefrainfrommakinginvestmentdecisionsbasedsolelyonthisdocument.TheCompanyshallnotbeliableforanydamageresultingfromtheuseofthisdocument.BrandMark“GreenPrism”,thesymbolofDainipponSumitomoPharmaCo.,Ltd.,isamotifinthedesignofthe“Sun”—expressingalivelysenseofenergy,movingontowardtomorrow;“Light”—toconveythepotentialandhopeofthefuture;and“Flower”—engenderingthejoyousandliberatedsensationofbaskingingoodhealth.Adesigncraftedtoembodypreeminentresearchanddevelopmentpowers,athoroughsupportsystem,thespiritofchallenge,andtheotherstancesofDainipponSumitomoPharma—acompanybentonsupplyingallpeoplewiththestrengthtopushontowardanevenbrightertomorrow.Thesymbolcolorof“DSPGreen”playsonthehueoffreshyoungleavesandotherimagesofhealthyandenergeticmoods,andsignsofwhatthefutureholds.Emanatingfromthesymbol,furthermore,istheimageofanetwork,steadilyspreadingoutintotheworld.ManagementMissionTocontributetohealthcareandpeople’swell-beingbasedupontheprinciplesofpatient-orientedmanagementandinnovativeresearchTocontinuouslystrivetomaximizecorporatevaluethroughconstantbusinessdevelopmentandtofulfillshareholderexpectationsTocreateanenvironmentinwhichemployeescanfulfilltheirpotentialandincreasetheircreativityTomaintainthetrustofsocietyandtocontributetotherealizationofabetterglobalenvironmentCorporateSloganHealthybodies,healthylives2ContentsCorporateProfileHighlightsoftheStatementsofIncomeBoardofDirectorsandExecutiveOfficersCorporateGovernanceProfilesofMajorProducts/3-YearSalesTrendofMajorProductsProfilesofMajorProductsunderDevelopmentAcquisitionofSepracorInc.FinancialOverviewMajorInvestmentIndicesBalanceSheetsStatementsofIncomeMajorOverseasBasesandOverseasPartnersHumanResourcesCorporateHistoryStockInformationCorporateProfile(asofSeptember30,2009)3Name:DainipponSumitomoPharmaCo.,Ltd.DateofMerger:October1,2005Capitalization:22.4billionyenRepresentatives:KenjiroMiyatake,ChairmanoftheBoardofDirectorsMasayoTada,PresidentandChiefExecutiveOfficerEmployees:4,740(non-consolidated;including1,480MRs)(asofSeptember30,2009)KeyFacilities:Headquarters(Chuo-ku,Osaka)TokyoOffice(Chuo-ku,Tokyo)OsakaCenter(Fukushima-ku,Osaka)25Branches4Plants(Suzuka,Ibaraki,Niihama,Oita)2ResearchLaboratories(Suita,Osaka)2DistributionCenters(Kazo,Kobe)StockExchanges:The1stSectionsofTokyo,OsakaListingsFiscalYear:April1toMarch31Independent:KPMGAZSA&Co.PublicAccountantsLeadManagers:(Main)DaiwaSecuritiesSMBCCo.Ltd.(Sub)NikkoCordialSecuritiesInc.MainBanks:SumitomoMitsuiBankingCorporation,TheBankofTokyo-MitsubishiUFJ,Ltd.TransferAgent:TheSumitomoTrust&BankingCo.,Ltd.42,6402,052290270180530HighlightsoftheStatementsofIncomeFiscalyearsendedMarch31,2008March31,2010(Forecast)NetSalesNetSalesofPharmaceuticalsOperatingincomeOrdinaryincomeNetincomeR&Dexpenditure2,6402,087398377256473March31,20092,6402,068312314200528ForecastsfortheyearendingMarch31,2010donotincludefiguresofSepracorInc..Goodwillandin-processR&Detc.resultingfromtheacquisitionareunderevaluationatpresent,andtheirfinancialimpactwillbeannouncedoncedetermined.Businesses:ManufacturingandsalesofpharmaceuticalsOtherbusinessesAnimalhealthbusiness(Salesofproductsforpets,livestockandmarineuse)Food&Specialityproductsbusiness(Salesofpolysaccharides,seasonings,electronicstoragematerials,pharmaceuticaladditives,etc.)Consolidated:subsidiaries2009hundredmillionsofyenGokyoTradingCo.,Ltd.SumitomoPharmaceuticals(Suzhou)Co.,Ltd.DSPharmaBiomedicalCo.,Ltd.October1947December2003¥100million$14million96.12%100%April2001¥480million100%Sale,exportandimportoffoodadditives,chemicalproductsandfinechemicalsResearch,development,manufacture,sale,importandexportofdiagnosticreagents,medicaldevicesandphysicochemistry-measuringinstrumentsformedicaluseEstablishmentPaid-incapitalOwnershipBusinessesManufacturing,salesofethicalpharmaceuticalsasofSeptember30,20095BoardofDirectorsandExecutiveOfficers(asofNovember12,2009)TitleNameResponsibilityRepresentativeDirector,KenjiroMiyatakeChairmanoftheBoardofDirectorsRepresentativeDirector,PresidentandMasayoTadaExecutiveDirector;InternationalBusinessChiefExecutiveOfficerMember,BoardofDirectors,SeniorExecutiveOfficerKeiichiOnoExecutiveDirector;DrugResearch,IntellectualPropertyMember,BoardofDirectors,SeniorExecutiveOfficerTetsuyaOidaExecutiveDirector;Non-PharmaceuticalOperations,PurchasingMember,BoardofDirectors,SeniorExecutiveOfficerYuichiYokoyamaExecutiveDirect